Market Overview

UPDATE: Citigroup Lowers PT on Abbott Laboratories Following In-Line 2Q13 Results

Share:
Related ABT
Benzinga's M&A Chatter for Thursday August 27, 2015
Benzinga's Volume Movers
Abbott's fully dissolving heart stent non-inferior to XIENCE stent in Japan study (Seeking Alpha)

In a report published Friday, Citigroup analyst Matthew J. Dodds reiterated a Sell rating on Abbott Laboratories (NYSE: ABT), and lowered the price target from $33.00 to $31.00.

In the report, Citigroup noted, “ABT's sales came in a bit light for the 2nd straight quarter and were in line with our forecast. Comparisons do get a bit easier in 2H but management's expectations of improvement nearly across the board still appear aggressive and likely need to be at least met in order to maintain the current premium valuation.”

Abbott Laboratories closed on Thursday at $35.70.

Latest Ratings for ABT

DateFirmActionFromTo
Aug 2015Credit SuisseAssumesOutperform
Aug 2015JefferiesMaintainsHold
Jul 2015BarclaysMaintainsEqual-weight

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: Citigroup Matthew J. DoddsAnalyst Color Price Target Analyst Ratings

 

Related Articles (ABT)

View Comments and Join the Discussion!

Get Benzinga's Newsletters